Monopar Therapeutics

Yahoo Finance • 20 days ago

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical nee... Full story

Yahoo Finance • 2 months ago

Broadcom Stock Sees Improved Relative Strength Rating

In a welcome move, Broadcom stock saw its Relative Strength Rating improve from 70 to 79 on Monday. See if Broadcom stock can continue to show renewed price strength and clear that threshold. Is Broadcom Stock A Buy? Continue Reading... Full story

Yahoo Finance • 5 months ago

Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05

* Monopar Therapeutics press release [https://seekingalpha.com/pr/20306013-monopar-therapeutics-reports-third-quarter-2025-financial-results-and-recent-developments] (MNPR [https://seekingalpha.com/symbol/MNPR]): Q3 GAAP EPS of -$0.48 mi... Full story

Yahoo Finance • 5 months ago

Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Northland upgraded DraftKings (DNKG) t... Full story

Yahoo Finance • 5 months ago

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, i... Full story

Yahoo Finance • 6 months ago

How the Narrative Around AstraZeneca Is Shifting Amid New Risks and Pipeline Developments

The consensus analyst price target for AstraZeneca has seen a slight upward revision, rising from £138.16 to £140.96, as market expectations are recalibrated. This adjustment comes amid evolving analyst perspectives that balance optimism a... Full story

Yahoo Finance • 6 months ago

Barclays initiates coverage on U.S. small & mid-cap biotech stocks

Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology I... Full story

Yahoo Finance • 7 months ago

Monopar Therapeutics announces pricing of $135M offering

* Monopar Therapeutics (NASDAQ:MNPR [https://seekingalpha.com/symbol/MNPR]) announced on Tuesday the pricing of an underwritten registered offering [https://seekingalpha.com/pr/20242206-monopar-therapeutics-inc-announces-pricing-of-135-m... Full story

Yahoo Finance • 7 months ago

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for patients w... Full story

Yahoo Finance • 7 months ago

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs,... Full story

Yahoo Finance • 7 months ago

CoreWeave upgraded, Lululemon downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Wells Fargo upgraded CoreWeave (CRWV)... Full story

Yahoo Finance • 7 months ago

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs,... Full story

Yahoo Finance • 7 months ago

Monopar a new outperform at Oppenheimer on Wilson disease candidate

[The New York Stock Exchange on the Wall street sign] Dmitry Vinogradov Oppenheimer has initiated Monopar Therapeutics at outperform citing the potential of a candidate for the genetic disorder Wilson disease it acquired from AstraZeneca... Full story

Yahoo Finance • 9 months ago

Monopar therapeutics director Tsuchimoto sells $356k in stock

Director Kim R. Tsuchimoto of Monopar Therapeutics (NASDAQ:MNPR), sold 8,904 shares of common stock on July 14, 2025. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, netting approximately $356,170. Th... Full story

Yahoo Finance • 9 months ago

Monopar therapeutics director Starr sells $672k in stock

Christopher M. Starr, a director at Monopar Therapeutics (NASDAQ:MNPR), sold 16,800 shares of common stock on July 14, 2025. The company’s stock has shown remarkable performance, with a 1,057% return over the past year, according to Invest... Full story

Yahoo Finance • 9 months ago

Monopar therapeutics CEO Chandler Robinson sells $672k in stock

Chandler Robinson, Chief Executive Officer of Monopar Therapeutics (NASDAQ:MNPR), sold 16,800 shares of common stock on July 14, 2025, according to a recent SEC Filing. The shares were sold at prices ranging from $40.00 to $40.25, for a to... Full story

Yahoo Finance • 10 months ago

Chardan initiates Monopar stock with buy rating on Wilson disease drug

Investing.com - Chardan Capital Markets initiated coverage on Monopar Therapeutics (NASDAQ:MNPR) with a buy rating and a $60 price target, citing potential in its late-stage Wilson disease treatment and early-stage radiopharmaceutical pipe... Full story

Yahoo Finance • 10 months ago

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatme... Full story

Yahoo Finance • 10 months ago

Monopar Therapeutics added to Russell 3000 and 2000 indexes, stock up 15%

Monopar Therapeutics (NASDAQ:MNPR [https://seekingalpha.com/symbol/MNPR]) will be added [https://seekingalpha.com/pr/20123970-monopar-therapeutics-announces-inclusion-in-the-russell-3000-and-russell-2000-indexes] to the broad-market Russel... Full story

Yahoo Finance • 11 months ago

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today... Full story